Brief: Sosei Heptares Says Entered Multi-Target Collaboration And License Agreement In Diabetes And Metabolic Diseases With Eli Lilly
16/12/2022 24:06
Dec 15 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES AND LILLY ENTER MULTI-TARGET COLLABORATION
AND
LICENSE AGREEMENT IN DIABETES AND METABOLIC DISEASES
* SOSEI - CO ELIGIBLE TO RECEIVE US$37 MILLION UPFRONT IN
CASH,
FURTHER DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS UP TO
US$694 MILLION PLUS TIERED ROYALTIES
Source text for Eikon: ID:nGNX6q0Bcy
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up